Meet ApplyKite Twin, the application assistant that learns with you
Meet your Twin, it learns with you
Your Twin learns with you
Launch week codes:30% off annual Pro20% off monthly Pro
Ends in00h00m00s
Ends in00h00m00s
Simo Schwartz
Has grant
Senior leading Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Autonomous Scanning Probe Microscopy for Life Sciences and Medicine powered by Artificial Intelligence (SPM4.0)
Open Date: 2025-01-01
Close Date: 2029-01-01
Grant: Open
Smart pathology slide scanner for diagnosis and patient-specific treatment recommendation in oncology (CancerScan).
Open Date: 2025-01-01
Close Date: 2029-01-01
Grant: Close
Breaking Barriers with Remote Integration for Global Pediatric Trials (BRIDGE)
Open Date: 2025-01-01
Close Date:
Grant: Close
Biodegradable and Eco-friendly Smart Hydrogels for the Sustained Intraperitoneal Release of Chemotherapeutics as a Novel Local Therapy Approach for Advanced Ovarian Cancer (HYDROTECH)
Open Date: 2024-01-01
Close Date: 2026-01-01
Grant: Close
EUROPEAN RARE DISEASES RESEARCH ALLIANCE (ERDERA)
Open Date: 2024-01-01
Close Date:
Articles (11)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2023
In this study, we developed functionalized polymeric micelles (FPMs) loaded with simvastatin (FPM-Sim) as a drug delivery system to target liver sinusoidal endothelial cells (LSECs) for preserving liver function in chronic liver disease (CLD). Polymeric micelles (PMs) were functionalized by coupling peptide ligands of LSEC membrane receptors CD32b, CD36 and ITGB3. Functionalization was confirmed via spectroscopy and electron microscopy. In vitro and in vivo FPM-Sim internalization was assessed by means of flow cytometry in LSECs, hepatocytes, Kupffer and hepatic stellate cells from healthy rats. Maximum tolerated dose assays were performed in healthy mice and efficacy studies of FPM-Sim were carried out in bile duct ligation (BDL) and thioacetamide (TAA) induction rat models of cirrhosis. Functionalization with the three peptide ligands resulted in stable formulations with a greater degree of in vivo internalization in LSECs than non-functionalized PMs. Administration of FPM-Sim in BDL rats reduced toxicity relative to free simvastatin, albeit with a moderate portal-pressure-lowering effect. In a less severe model of TAA-induced cirrhosis, treatment with FPM-CD32b-Sim nanoparticles for two weeks significantly decreased portal pressure, which was associated with a reduction in liver fibrosis, lower collagen expression as well as the stimulation of nitric oxide synthesis. In conclusion, CD32b-FPM stands out as a good nanotransporter for drug delivery, targeting LSECs, key inducers of liver injury.
Year:
2023
Year:
2023
Collaborators (14)
Ibane Abasolo
-
Bruno Sarmento
Principal Investigator
Cooperativa de Ensino Superior Politécnico e Universitário
Higinio Dopeso
Senior Research Scientist
Sloan Kettering Institute
Diana Rafael
Vall d'Hebron Research Institute
Manuel Sanchez-Martin
Lecturer
Universidad de Salamanca
María Martell
Vall d'Hebron Institut de Recerca
Xavier Trepat
Research Professor
Instituciò Catalana de Recerca i Estudis Avancats
Laura Mondragon Martinez
Junior Group Leader (Ramón y Cajal contract 2019)
Josep Carreras Leukaemia Research Institute
Simon Clark
Prof. at University of Tübingen
University of Tübingen
Ricard Farré
Professor
Associatie KU Leuven
Pilar Sánchez-Gómez
Full Professor
Instituto de Salud Carlos III Campus de Majadahonda
Seyed Moein Moghimi
Professor
Newcastle University
Fernanda Andrade
Principal Investigator
Universitat Autònoma de Barcelona Facultat de Medicina
Joaquin Seras-Franzoso
Vall d'Hebron Institut de Recerca
Make your next move.
Prepare your application
Review drafts before you send them.